This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Haemophagocytic lymphohistiocytosis
D3_HAEMOPHAGOLYMPHO
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
57 |
4. Check minimum number of eventsNone |
57 |
5. Include endpointsNone |
57 |
6. Filter based on genotype QC (FinnGen only) |
49 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D76
- Name in latin
- Lymphohistiocytosis haemophagocytica
Similar endpoints
↥List of similar endpoints to
Haemophagocytic lymphohistiocytosis
based on the number of shared cases.
Similar with more cases:
- Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 229 | 104 | 124 |
| Only index persons | 190 | 85 | 105 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | 0.00 |
| Only index persons | 0.00 | 0.00 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 53.33 | 53.45 | 53.32 |
| Only index persons | 60.41 | 60.93 | 59.99 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 49 | 20 | 29 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 58.80 | 55.46 | 61.10 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 51
- Matched controls
- 510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D76.1
ICD-10 Finland
Haemophagocytic lymphohistiocytosis
+∞
73.0
51
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
14.7
21.5
28
39
XW000
NOMESCO Finland
Bone marrow biopsy
80.9
21.4
23
5
R50.9
ICD-10 Finland
Fever, unspecified
12.6
19.3
31
56
JN4AD
NOMESCO Finland
Body CT examination
11.0
16.2
24
38
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
9.9
15.6
29
60
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
44.9
15.1
18
6
JN4BD
NOMESCO Finland
Extensive body CT
15.1
13.1
23
26
WW500
NOMESCO Finland
Blood transfusion
22.4
13.1
19
13
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
8.5
12.1
21
39
H02AB09
ATC
hydrocortisone; systemic
34.0
10.4
13
5
H02AB02
ATC
dexamethasone; systemic
7.4
10.3
20
41
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
15.3
10.3
17
16
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
20.8
9.7
14
9
GD1AD
NOMESCO Finland
Thorax CT examination
14.9
9.6
16
15
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
12.8
9.5
17
19
H02AB06
ATC
prednisolone; systemic
7.8
9.4
41
176
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
9.4
8.8
19
30
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.2
8.7
20
48
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
+∞
8.6
8
*
JN6AD
NOMESCO Finland
CT of torso and neck
+∞
8.6
8
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.3
7.9
40
186
D76.01
ICD-10 Finland
Histiocytosis X (chronic)
+∞
7.5
7
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
10.9
7.4
14
17
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
35.6
7.4
9
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
12.0
7.3
13
14
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.0
7.3
11
8
L03AA02
ATC
filgrastim; parenteral
20.2
7.1
10
6
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.5
6.8
13
16
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.6
6.7
24
82
N17.9
ICD-10 Finland
Acute renal failure, unspecified
13.6
6.7
11
10
UGC12
NOMESCO Finland
Flexible bronchoscopy
9.8
6.6
13
17
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.7
6.6
14
21
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
21.4
6.5
9
5
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.3
6.4
13
18
TPX10
NOMESCO Finland
Implantation of vascular injection port
15.1
6.4
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
12
45.69
22.19
2.4
1.6
—
—
—
0
0
25
32
14.36
20.22
4.1
1.6
—
—
—
0
0
20
6
53.00
17.34
3.6
4.5
—
—
—
0
0
20
6
53.00
17.34
3.8
4.0
15.65
9.00
%
—
20
6
25
39
11.61
17.21
14.0
14.0
12.87
9.57
mmol/l
0.88
25
39
15
0
+∞
16.53
2.3
0.0
—
—
—
0
0
20
9
35.28
15.77
1.5
1.4
—
—
—
0
0
21
12
28.57
15.53
4.4
1.2
—
—
—
0
0
23
18
22.15
15.42
4.5
1.3
—
—
—
0
0
35
91
10.07
15.30
18.1
5.1
0.78
0.82
mmol/l
1.13
35
85
22
17
21.71
14.74
3.7
1.2
—
—
—
0
0
19
9
32.50
14.71
1.7
1.9
—
—
—
0
0
22
19
19.35
14.11
1.8
1.2
—
—
—
0
0
22
20
18.36
13.81
3.1
2.3
—
—
—
0
0
22
20
18.36
13.81
11.5
1.8
83.18
91.15
%
0.42
22
20
22
20
18.36
13.81
1.8
1.2
—
—
—
0
0
32
86
8.30
13.15
5.8
1.6
—
—
—
0
0
34
102
8.00
12.36
10.1
1.8
4.72
1.80
mg/l
1.29
34
85
16
8
28.26
12.06
2.4
1.3
—
—
—
0
0
11
0
+∞
11.92
1.5
0.0
—
—
—
0
0
27
67
7.44
11.78
4.0
1.5
—
—
—
0
0
38
134
8.20
11.48
7.3
2.7
297.74
365.19
umol/l
2.65
38
118
28
75
7.06
11.22
3.6
3.3
1.85
2.33
g/l
2.56
28
69
17
13
18.87
11.17
2.2
1.2
—
—
—
0
0
10
0
+∞
10.79
1.6
0.0
—
—
—
0
0
10
0
+∞
10.79
1.7
0.0
—
—
—
0
0
17
15
16.30
10.55
2.0
1.9
—
—
—
0
0
17
15
16.30
10.55
1.9
1.2
—
—
—
0
0
25
64
6.70
10.37
3.7
1.5
—
—
—
0
0
28
80
6.54
10.35
3.9
3.2
12.07
12.93
umol/l
0.21
28
75
15
10
20.55
10.30
2.5
1.3
—
—
—
0
0
17
17
14.34
9.99
1.9
1.2
—
—
—
0
0
13
6
28.29
9.94
5.8
1.0
—
—
—
0
0
22
54
6.41
9.42
6.2
4.1
25.27
10.23
umol/l
1.16
22
47
14
13
14.31
8.43
2.1
1.7
—
—
—
0
0
11
5
27.36
8.43
6.7
1.0
—
—
—
0
0
13
13
12.95
7.57
1.4
1.2
—
—
—
0
0
43
234
6.32
7.04
38.0
10.3
1.21
1.21
mmol/l
0.11
33
209
17
42
5.57
7.01
23.8
9.0
1.41
1.31
mmol/l
0.23
17
42
11
9
15.14
6.96
1.9
1.2
—
—
—
0
0
13
16
10.47
6.84
15.6
2.1
207.77
205.56
%
0.02
13
16
41
209
5.90
6.82
12.1
2.9
—
—
estimate
—
0
0
46
279
7.60
6.73
62.8
10.3
4.22
4.20
e9/l
0.01
46
238
10
7
17.31
6.71
2.1
1.3
—
—
—
0
0
9
5
21.35
6.52
1.2
1.0
—
—
—
0
0
11
11
12.35
6.40
2.1
1.5
410.73
529.36
mg/l
0.27
11
11
10
8
15.13
6.39
2.1
1.3
3.60
3.58
mmol/l
—
10
8
26
105
4.01
5.62
12.6
2.2
—
—
—
0
0
10
11
10.96
5.58
1.2
1.1
—
—
—
0
0
9
8
13.31
5.53
1.7
1.3
—
—
—
0
0
9
8
13.31
5.53
1.7
1.3
—
—
—
0
0
5
0
+∞
5.29
1.0
0.0
—
—
—
0
0
5
0
+∞
5.29
1.0
0.0
—
—
—
0
0
5
0
+∞
5.29
2.8
0.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
0
+∞
5.29
1.6
0.0
—
—
—
0
0
5
0
+∞
5.29
1.6
0.0
—
—
—
0
0
20
70
4.06
5.23
26.7
8.6
103.85
103.99
mmol/l
0.05
20
70
8
7
13.23
4.97
2.0
1.0
—
—
—
0
0
17
56
4.05
4.78
7.4
17.7
-0.13
1.03
mmol/l
0.64
12
46
8
8
11.56
4.70
2.0
1.1
—
—
—
0
0
17
57
3.97
4.65
7.4
17.2
4.19
5.12
kpa
5.44
17
52
9
13
8.13
4.38
2.6
1.3
—
—
—
0
0
9
13
8.13
4.38
3.0
1.5
—
—
—
0
0
16
54
3.86
4.31
3.8
2.8
256.81
385.10
nmol/l
2.68
16
49
9
14
7.54
4.19
3.4
1.0
0.00
0.00
g/l
—
9
14
7
7
11.32
4.14
2.1
1.3
—
—
—
0
0
12
29
5.08
4.03
9.8
12.8
94.83
95.13
%
0.17
12
29
14
45
3.91
4.01
8.1
2.7
—
—
—
0
0
13
43
3.72
3.55
33.0
10.0
23.16
24.59
mmol/l
0.75
13
43
6
7
9.50
3.35
1.8
2.1
—
—
—
0
0
21
98
2.94
3.30
1.4
1.2
60.33
24.38
iu/ml
—
6
32
30
171
2.83
3.23
3.6
3.2
2.24
2.35
mmol/l
2.37
30
155
11
31
4.23
3.23
3.8
1.4
—
—
—
0
0
46
347
4.31
3.21
13.3
4.5
26.30
10.92
mm/h
2.34
46
323
8
16
5.71
3.19
1.8
1.4
—
—
—
0
0
9
22
4.73
3.05
2.8
1.3
—
—
—
0
0
5
5
10.88
3.04
1.2
1.2
35.40
10.40
u/l
—
5
5
5
5
10.88
3.04
1.0
1.2
—
—
—
0
0
5
5
10.88
3.04
1.0
1.2
—
—
—
0
0
5
6
9.06
2.81
1.4
1.3
—
—
—
0
0
7
15
5.22
2.70
7.7
1.9
—
—
—
0
0
7
15
5.22
2.70
1.9
1.5
—
—
—
0
0
5
8
6.78
2.42
5.0
3.6
—
—
—
0
0
5
8
6.78
2.42
1.2
1.4
—
—
—
0
0
23
131
2.38
2.29
8.8
4.2
0.00
0.00
estimate
-0.00
12
47
35
244
2.38
2.14
8.7
4.3
0.00
0.00
estimate
-0.00
13
49
35
248
2.31
2.00
8.6
4.4
0.00
0.00
estimate
-0.00
12
48
35
248
2.31
2.00
8.7
4.3
0.00
0.00
estimate
-0.00
13
51
16
82
2.39
1.97
1.3
1.2
53.32
3.93
u/ml
—
5
26
28
189
2.07
1.72
7.8
4.1
0.00
0.00
estimate
-0.00
13
45
7
27
2.84
1.58
42.7
2.6
1.07
1.05
%
—
7
27
5
15
3.57
1.56
2.6
1.3
—
—
—
0
0
6
21
3.10
1.55
5.2
2.7
22.80
24.71
mmol/l
—
6
21
27
190
1.89
1.39
3.2
2.2
79.36
94.77
pmol/l
1.32
22
94
37
432
0.48
1.38
5.5
6.5
38.61
39.46
mmol/mol
0.16
31
408
8
34
2.60
1.36
51.6
5.8
23.50
23.51
mmol/l
—
8
34
9
44
2.27
1.35
1.9
3.3
33.56
27.94
u/l
—
9
35
29
216
1.79
1.19
4.3
3.0
76.31
73.07
nmol/l
0.36
29
200
21
142
1.81
1.18
3.8
2.1
63.14
165.61
u/l
3.15
21
133
41
342
2.01
1.14
4.3
4.4
14.47
14.85
pmol/l
0.42
41
309
14
85
1.89
1.08
7.5
3.9
1.38
0.86
e6/l
—
9
45
16
104
1.78
1.00
3.7
3.3
2.44
2.47
mmol/l
0.54
16
88
15
97
1.77
0.95
5.1
3.3
45.53
413.61
ng/l
0.75
15
80
14
92
1.72
0.83
6.9
3.9
1.64
0.79
e6/l
—
9
51
20
149
1.56
0.73
8.8
3.8
0.00
0.00
estimate
-0.00
13
44
36
406
0.61
0.73
82.6
20.2
330.82
333.67
g/l
0.94
36
406
45
412
1.78
0.59
5.1
5.3
1.90
1.95
mu/l
0.09
45
376
14
101
1.53
0.57
2.1
1.8
541.86
463.30
pmol/l
0.30
14
87
12
93
1.38
0.34
2.1
1.8
—
—
—
0
0
6
49
1.25
0.21
19.5
8.4
—
—
—
0
0
6
52
1.17
0.20
2.7
4.7
20.33
30.48
%
—
6
29
43
415
1.23
0.15
69.6
16.3
79.21
80.27
ml/min/173m2
0.11
43
389
5
47
1.07
0.10
2.4
1.4
—
—
—
0
0
14
128
1.13
0.07
1.5
1.6
2.82
1.80
u/ml
—
5
33
30
292
1.07
0.02
4.8
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_HAEMOPHAGOLYMPHO and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have D3_HAEMOPHAGOLYMPHO.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: D3_HAEMOPHAGOLYMPHO – Haemophagocytic lymphohistiocytosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data